Last week, GW Pharma (NASDAQ: GWPH) scored a milestone victory, as the thirteen-member panel at the Peripheral and Central Nervous System Drugs Advisory Committee, which met on April 19th to consider...

The potentially first botanically-derived FDA-approved cannabis-based product moved closer to approval today, as an Advisory Committee discussed the safety and efficacy of Epidolex, intended to treat seizures in children...

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome...

Confirming reports from unnamed sources published last night, Chuck Rosenberg, the Acting Administrator of the Drug Enforcement Agency (DEA), issued a harshly worded 186-page rejection of a request by former Governors...

Most investors understand the importance of listening to quarterly conference calls, as companies will often reveal important information in either the prepared remarks or the Q&A that follows that isn’t conveyed...